Tocagen (NASDAQ:TOCA) Stock Rating Upgraded by ValuEngine

Tocagen (NASDAQ:TOCA) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Friday, November 2nd.

A number of other brokerages have also weighed in on TOCA. BidaskClub raised shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. B. Riley upped their target price on shares of Tocagen from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, September 20th. Citigroup assumed coverage on shares of Tocagen in a research note on Tuesday, September 4th. They issued a “buy” rating and a $27.00 target price for the company. Zacks Investment Research lowered shares of Tocagen from a “hold” rating to a “sell” rating in a research note on Thursday, August 16th. Finally, Chardan Capital assumed coverage on shares of Tocagen in a research note on Thursday, August 30th. They issued a “buy” rating and a $30.00 target price for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Tocagen currently has an average rating of “Buy” and a consensus target price of $20.75.

Shares of TOCA stock traded up $0.78 on Friday, hitting $13.08. The stock had a trading volume of 184,495 shares, compared to its average volume of 165,769. Tocagen has a twelve month low of $7.52 and a twelve month high of $15.80. The firm has a market capitalization of $240.61 million, a price-to-earnings ratio of -4.92 and a beta of 2.84. The company has a quick ratio of 6.06, a current ratio of 6.06 and a debt-to-equity ratio of 0.56.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.22. The company had revenue of $18.01 million during the quarter, compared to analyst estimates of $2.01 million. Tocagen had a negative net margin of 130,944.75% and a negative return on equity of 77.46%. Research analysts expect that Tocagen will post -2.69 earnings per share for the current year.

A number of large investors have recently modified their holdings of TOCA. Raymond James & Associates bought a new stake in Tocagen during the 2nd quarter worth about $142,000. First Republic Investment Management Inc. bought a new stake in Tocagen during the 2nd quarter worth about $170,000. Beaumont Financial Partners LLC bought a new stake in Tocagen during the 3rd quarter worth about $212,000. Granahan Investment Management Inc. MA lifted its position in Tocagen by 16.0% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 42,438 shares of the company’s stock worth $396,000 after buying an additional 5,839 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Tocagen during the 1st quarter worth about $402,000. 28.00% of the stock is currently owned by hedge funds and other institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: Bond

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply